The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer

Carcinogenesis

Volumn 37, Issue 12, 2016, Pages 1170-1179

  Leal, Ana S ^a,b   Sporn, Michael B ^a   Pioli, Patricia A ^a   Liby, Karen T ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OIC ACID IMIDAZOLIDE; BARDOXOLONE; CD11B ANTIGEN; CD45 ANTIGEN; COLONY STIMULATING FACTOR 1; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; K RAS PROTEIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR PDX 1; TRITERPENOID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; 1-(2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OYL) IMIDAZOLE; CCL12 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; IMIDAZOLE DERIVATIVE; KRAS2 PROTEIN, MOUSE; MONOCYTE CHEMOTACTIC PROTEIN; OLEANOLIC ACID; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; PROTEIN P21; PTPRC PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL INFILTRATION; CELL SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; IMMUNOCOMPETENT CELL; MALE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SPLEEN; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CHRONIC PANCREATITIS; COMPLICATION; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; NEOPLASMS, EXPERIMENTAL; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIGENS, CD45; GRANULOCYTE COLONY-STIMULATING FACTOR; HOMEODOMAIN PROTEINS; HUMANS; IMIDAZOLES; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; MONOCYTE CHEMOATTRACTANT PROTEINS; NEOPLASMS, EXPERIMENTAL; OLEANOLIC ACID; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROTO-ONCOGENE PROTEINS P21(RAS); TRANS-ACTIVATORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85015990141     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw099     Document Type: Article

References (55)

1. Siegel, R.L. et al. (2015) Cancer statistics, 2015. CA. Cancer J. Clin., 65, 5-29.
2. de Sousa Cavalcante, L. et al. (2014) Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol., 741, 8-16.
3. Conroy, T. et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med., 364, 1817-1825.
4. Neesse, A. et al. (2014) nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Zeitschrift fur Gastroenterologie, 52, 360-366.
5. Chin, L. et al. (2013) Recapitulating human cancer in a mouse. Nat. Biotechnol., 31, 392-395.
6. Hingorani, S.R. et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4, 437-450.
7. Zheng, L. et al. (2013) Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology, 144, 1230-1240.
8. Crusz, S.M. et al. (2015) Inflammation and cancer: advances and new agents. Nat. Rev. Clin. Oncol., 12, 584-596.
9. Clark, C.E. et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res., 67, 9518-9527.
10. Guerra, C. et al. (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell, 11, 291-302.
11. Daniluk, J. et al. (2012) An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J. Clin. Invest., 122, 1519-1528.
12. Carrière, C. et al. (2009) Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem. Biophys. Res. Commun., 382, 561-565.
13. Yadav, D. et al. (2013) The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology, 144, 1252-1261.
14. Aghdassi, A.A. et al. (2011) Animal models for investigating chronic pancreatitis. Fibrogenesis Tissue Repair, 4, 26.
15. Sun, B. et al. (2014) The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol. Sci., 35, 349-357.
16. Liby, K.T. et al. (2012) Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev., 64, 972-1003.
17. Auletta, J.J. et al. (2010) The synthetic triterpenoid, CDDO-Me, modulates the proinflammatory response to in vivo lipopolysaccharide challenge. J. Interferon Cytokine Res., 30, 497-508.
18. Vannini, N. et al. (2007) The synthetic oleanane triterpenoid, CDDOmethyl ester, is a potent antiangiogenic agent. Mol. Cancer Ther., 6(12 Pt 1), 3139-3146.
19. Tran, K. et al. (2012) The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev. Res., 5, 726-734.
20. Ball, M.S. et al. (2016) CDDO-Me redirects activation of breast tumor associated macrophages. PLoS One, 11, e0149600.
21. Nagaraj, S. et al. (2010) Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res., 16, 1812-1823.
22. Probst, B.L. et al. (2015) RTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS One, 10, e0122942.
23. Liby, K.T. et al. (2010) Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev. Res., 3, 1427-1434.
24. Honda, T. et al. (2002) A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett., 12, 1027-1030.
25. Cao, M. et al. (2015) Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol. Res., 100, 135-147.
26. Bayne, L.J. et al. (2012) Tumor-derived granulocyte-macrophage colonystimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell, 21, 822-835.
27. Pylayeva-Gupta, Y. et al. (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell, 21, 836-847.
28. Apte, M.V. et al. (2013) A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology, 144, 1210-1219.
29. Vonderheide, R.H. et al. (2013) Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr. Opin. Immunol., 25, 200-205.
30. Phan, V.T. et al. (2013) Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc. Natl. Acad. Sci. USA, 110, 6079-6084.
31. Holmer, R. et al. (2014) Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat. Dis. Int., 13, 371-380.
32. Zhang, Y. et al. (2013) Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res., 73, 6359-6374.
33. Arlt, A. et al. (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res., 62, 910-916.
34. Barber, M.D. et al. (2000) A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer, 83, 1443-1447.
35. Sanford, D.E. et al. (2013) Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin. Cancer Res., 19, 3404-3415.
36. Niedergethmann, M. et al. (2002) High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas, 25, 122-129.
37. Zhu, Y. et al. (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res., 74, 5057-5069.
38. Pyonteck, S.M. et al. (2012) Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene, 31, 1459-1467.
39. Thimmulappa, R.K. et al. (2006) Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest., 116, 984-995.
40. Thimmulappa, R.K. et al. (2007) Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid. Redox Signal., 9, 1963-1970.
41. Liao, D. et al. (2011) Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res., 71, 5688-5696.
42. Jiang, Y. et al. (2013) Altered sphingolipid metabolism in patients with metastatic pancreatic cancer. Biomolecules, 3, 435-448.
43. Yip-Schneider, M.T. et al. (2013) Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer, 13, 194.
44. Parsons, B.L. et al. (2009) K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark. Med., 3, 757-769.
45. Michaud, D.S. (2013) Role of bacterial infections in pancreatic cancer. Carcinogenesis, 34, 2193-2197.
46. Amiot, F. et al. (1997) Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice. Mol. Med., 3, 864-875.
47. Smit, M.A. et al. (2014) Cancer immunoprevention-the next frontier. Cancer Prev. Res., 7, 1072-1080.
48. Najjar, Y.G. et al. (2013) Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front. Oncol., 3, 49.
49. Mielgo, A. et al. (2013) Impact of tumour associated macrophages in pancreatic cancer. BMB Rep., 46, 131-138.
50. Mohammed, A. et al. (2015) Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Oncotarget, 6, 15524-15539.
51. Husain, K. et al. (2013) Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E d-tocotrienol. Carcinogenesis, 34, 858-863.
52. To, C. et al. (2015) Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis, 7, 769-81.
53. Sporn, M.B. (2011) Perspective: the big C -for chemoprevention. Nature, 471, S10-S11.
54. Klein, A.P. et al. (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res., 64, 2634-2638.
55. Singh, M. et al. (2007) Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology, 7, 9-19.